Anticancer therapy

• US 9,610,371 B2
• Filed: 03/26/2015
• Issued: 04/04/2017
• Est. Priority Date: 07/29/2005
• Status: Active Grant

• Current Assignee: UNM Rainforest Innovations (f/k/a STC.UNM) (The University of New Mexico)
• Original Assignee: UNM Rainforest Innovations (f/k/a STC.UNM) (The University of New Mexico)
• Inventors: Norenberg, Jeffrey P.
• Primary Examiner(s): Jones, D L
• Application Number:
  US14/669,313
• Publication Number:
  US 20150196673A1
• Time in Patent Office: 740 Days
• Field of Search: 424 111, 424 149, 424 153, 424 165, 424 173, 424 91, 424 93, 424 94, 424 95, 424 96, 424 97, 424 98, 534 7, 534 10- 16, 530300, 530311, 530317, 530328, 514 1, 514 11, 514 192, 514 193, 514 194, 514 195, 514 196, 514 211, 514 216, 514 215, 514 111
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• CPC Class Codes: A61K 38/31 Somatostatins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 51/08 Peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
• CPC Class Codes: A61K 51/083 the peptide being octreotide or a somatostatin-receptor-binding peptide
• CPC Class Codes: A61K 51/088 conjugates with carriers being peptides, polyamino acids or proteins antibodies A61K51/10

Abstract

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

Claims

1. A method of treating a somatostatin receptor expressing cancerous tumor in a patient in need, the method comprising administering to said patient an effective amount of a composition comprising a chelate-linked peptide analog of somatostatin comprising a radionuclide, wherein said peptide analog of somatostatin is Tyr³-Octreotide, said chelate is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and said radionuclide is the α

particle emitter ²¹³Bi (²¹³Bi-DOTATOC), in a pharmaceutically acceptable carrier, in combination with an additional anti-cancer compound, wherein said additional anti-cancer compound is Aldesleukin;

Alemtuzumab;

alitretinoin;

allopurinol;

altretamine;

amifostine;

anastrozole;

arsenic trioxide;

Asparaginase;

BCG Live;

bexarotene capsules;

bexarotene gel;

bleomycin;

busulfan intravenous;

busulfan oral;

calusterone;

capecitabine;

carboplatin;

carmustine;

carmustine with Polifeprosan 20 Implant;

celecoxib;

chlorambucil;

cisplatin;

cladribine;

cyclophosphamide;

cytarabine;

cytarabine liposomal;

dacarbazine;

dactinomycin, actinomycin D;

Darbepoetin alfa;

daunorubicin liposomal;

daunorubicin, daunomycin;

Denileukin diftitox, dexrazoxane;

docetaxel;

doxorubicin;

doxorubicin liposomal;

Dromostanolone propionate;

Elliott'"'"'s B Solution;

epirubicin;

Epoetin alfa estramustine;

etoposide phosphate;

etoposide (VP-16);

exemestane;

Filgrastim;

floxuridine (intraarterial);

fludarabine;

fluorouracil (5-FU);

fulvestrant;

gemtuzumab ozogamicin;

gleevec (imatinib);

goserelin acetate;

hydroxyurea;

Ibritumomab Tiuxetan;

idarubicin;

ifosfamide;

imatinib mesylate;

Interferon alfa-2a;

Interferon alfa-2b;

irinotecan;

letrozole;

leucovorin;

levamisole;

lomustine (CCNU);

meclorethamine (nitrogen mustard);

megestrol acetate;

melphalan (L-PAM);

mercaptopurine (6-MP);

mesna;

methotrexate;

methoxsalen;

mitomycin C;

mitotane;

mitoxantrone;

nandrolone phenpropionate;

Nofetumomab;

LOddC;

Oprelvekin;

oxaliplatin;

paclitaxel;

pamidronate;

pegademase;

Pegaspargase;

Pegfilgrastim;

pentostatin;

pipobroman;

plicamycin;

mithramycin;

porfimer sodium;

procarbazine;

quinacrine;

Rasburicase;

Rituximab;

Sargramostim;

streptozocin;

surafenib;

talbuvidine (LDT);

talc;

tamoxifen;

tarceva (erlotinib);

temozolomide;

teniposide (VM-26);

testolactone;

thioguanine (6-TG);

thiotepa;

topotecan;

toremifene;

Tositumomab;

Trastuzumab;

tretinoinjATRA);

Uracil Mustard;

valrubicin;

valtorcitabine (monoval LDC);

vinblastine;

vinorelbine;

zoledronate;

or a mixture thereof.

2. The method according to claim 1 wherein said cancerous tumor is a cancer of the breast, pancreas, stomach, prostate, kidney, colon, rectal, thyroid, lung, kidney, liver, brain/central nervous system or lymph (malignant lymphoid cancer).

3. The method according to claim 2 wherein said cancerous tumor is a cancer of the breast, pancreas, prostate or thyroid.

4. The method according to claim 3 wherein said cancerous tumor is a cancer of the pancreas.

5. The method according to claim 2 wherein said brain/central nervous system tumor is a meningioma, astrocytoma or glioma.

6. A method of treating a somatostatin receptor expressing cancerous tumor in a patient in need, the method comprising administering to said patient an effective amount of a composition comprising a chelate-linked peptide analog of somatostatin comprising a radionuclide, wherein said peptide analog of somatostatin is Tyr³-Octreotide, said chelate is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and said radionuclide is the α

particle emitter ²¹³Bi (²¹³Bi-DOTATOC), in a pharmaceutically acceptable carrier, in combination with an additional anti-cancer compound, wherein said additional anti-cancer compound is gemcitabine, fluorouracil, irinotecan, oxaliplatin, paclitaxel, docetaxel, capecitabine or a mixture thereof.

7. The method according to claim 6 wherein said cancerous tumor is a cancer of the breast, pancreas, stomach, prostate, kidney, colon, rectal, thyroid, lung, kidney, liver, brain/central nervous system or lymph (malignant lymphoid cancer).